7 June 2023 - NICE has published final evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the  treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.

Axicabtagene ciloleucel is recommended for use within the Cancer Drugs Fund as an option for the treatment of adults with diffuse large B‑cell lymphoma when an autologous stem cell transplant is suitable if it has relapsed within 12 months after first-line chemoimmunotherapy or is refractory to first-line chemoimmunotherapy.

Read NICE technology appraisal guidance